In a phase 2 trial of 60 medically unfit adults with untreated AML, 3-month overall survival was 70% with CLAG-M vs 60% with CPX-351 (P = 0.41); only CLAG-M met the ≥63% target. Median OS did not differ significantly (10.5 vs 5.8 months).
RCTn = 60
Halpern et al. Randomized phase 2 trial of CPX-351 vs. CLAG-M (cladribine, cytarabine, G-CSF, and mitoxantrone) for medically unfit adults with acute myeloid leukemia or other high-grade myeloid neoplasms